

# Yves Fradet

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/10383999/yves-fradet-publications-by-year.pdf>

**Version:** 2023-03-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

54  
papers

6,307  
citations

32  
h-index

55  
g-index

55  
ext. papers

7,640  
ext. citations

7.9  
avg, IF

4.92  
L-index

#	Paper	IF	Citations
54	Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results From the KEYNOTE-045 and KEYNOTE-052 Landmark Trials.. <i>Clinical Cancer Research</i> , <b>2022</b> ,	12.3	1
53	Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial. <i>Lancet Oncology, The</i> , <b>2021</b> , 22, 931-945	20.9	51
52	Building a Canadian Translational Bladder Cancer Research Network. <i>Canadian Urological Association Journal</i> , <b>2020</b> , 14, E475-E481	1.2	
51	Receipt of 5-Alpha Reductase Inhibitors Before Radical Cystectomy: Do They Render High-Grade Bladder Tumors Less Aggressive?. <i>Clinical Genitourinary Cancer</i> , <b>2019</b> , 17, e1122-e1128	3.2	7
50	Genome-wide germline correlates of the epigenetic landscape of prostate cancer. <i>Nature Medicine</i> , <b>2019</b> , 25, 1615-1626	49.3	23
49	Use and duration of antibiotic prophylaxis and the rate of urinary tract infection after radical cystectomy for bladder cancer: Results of a multicentric series. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2019</b> , 37, 300.e9-300.e15	2.7	10
48	Widespread and Functional RNA Circularization in Localized Prostate Cancer. <i>Cell</i> , <b>2019</b> , 176, 831-843.e234.5	34.5	210
47	A Comprehensive Analysis of Steroid Hormones and Progression of Localized High-Risk Prostate Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2019</b> , 28, 701-706	3.6	5
46	Improving patient journey and quality of care: Summary from the second Bladder Cancer Canada-Canadian Urological Association-Canadian Urologic Oncology Group (BCC-CUA-CUOG) bladder cancer quality of care consensus meeting. <i>Canadian Urological Association Journal</i> , <b>2018</b> , 13, E001-E007	1.2	6
45	Health-Related Quality-of-Life Analysis From KEYNOTE-045: A Phase III Study of Pembrolizumab Versus Chemotherapy for Previously Treated Advanced Urothelial Cancer. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 1579-1587	2.1	69
44	A Festschrift in Honor of Edward M. Messing, MD, FACS. <i>Bladder Cancer</i> , <b>2018</b> , 4, S1-S43	0.9	
43	Quality indicators in the management of bladder cancer: A modified Delphi study. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2017</b> , 35, 328-334	2.7	16
42	Genomic hallmarks of localized, non-indolent prostate cancer. <i>Nature</i> , <b>2017</b> , 541, 359-364	47.5	322
41	Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. <i>New England Journal of Medicine</i> , <b>2017</b> , 376, 1015-1026	57.2	1784
40	A Prostate Cancer "Nimbus": Genomic Instability and SCHLAP1 Dysregulation Underpin Aggression of Intraductal and Cribriform Subpathologies. <i>European Urology</i> , <b>2017</b> , 72, 665-674	9.9	98
39	Phase II Drug-Metabolizing Polymorphisms and Smoking Predict Recurrence of Non-Muscle-Invasive Bladder Cancer: A Gene-Smoking Interaction. <i>Cancer Prevention Research</i> , <b>2016</b> , 9, 189-95	3.1	7
38	Recommendations for the improvement of bladder cancer quality of care in Canada: A consensus document reviewed and endorsed by Bladder Cancer Canada (BCC), Canadian Urologic Oncology Group (CUOG), and Canadian Urological Association (CUA), December 2015. <i>Canadian Urological Association Journal</i> , <b>2016</b> , 10, E16-60	1.2	40

37	Copy number alterations of P53, RB1, and MDM2 as prognostic markers in intermediate-risk prostate cancer.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 117-117	2.1	
36	Copy number alterations of DNA mismatch repair (MMR) genes as novel prognostic markers in localised prostate cancer (CaP).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 96-96	2.1	
35	Prognostic value of copy-number alterations of the Cohesin complex in intermediate-risk prostate cancer recurrence.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 49-49	2.1	
34	Combinatorial genomic and pathological indices for integrated stratification of unfavorable intermediate-risk prostate cancer.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 5051-5051	2.1	
33	Molecular markers for bladder cancer screening, early diagnosis, and surveillance: the WHO/ICUD consensus. <i>Urologia Internationalis</i> , <b>2015</b> , 94, 1-24	1.8	118
32	Comparison of digital image analysis and visual scoring of KI-67 in prostate cancer prognosis after prostatectomy. <i>Diagnostic Pathology</i> , <b>2015</b> , 10, 67	2.9	18
31	Impact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302. <i>European Urology</i> , <b>2015</b> , 68, 570-7	9.9	41
30	Adjuvant chemotherapy for upper-tract urothelial carcinoma treated with nephroureterectomy: assessment of adequate renal function and influence on outcome. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2014</b> , 32, 31.e17-24	2.7	39
29	Gender-specific differences in clinicopathologic outcomes following radical cystectomy: an international multi-institutional study of more than 8000 patients. <i>European Urology</i> , <b>2014</b> , 66, 913-9	9.9	73
28	Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302). <i>European Urology</i> , <b>2014</b> , 66, 815-25	9.9	184
27	Effect of body mass index on the outcomes of patients with upper and lower urinary tract cancers treated by radical surgery: results from a Canadian multicenter collaboration. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2014</b> , 32, 441-8	2.7	23
26	Steroidogenic germline polymorphism predictors of prostate cancer progression in the estradiol pathway. <i>Clinical Cancer Research</i> , <b>2014</b> , 20, 2971-83	12.3	25
25	Initial prostate biopsy: development and internal validation of a biopsy-specific nomogram based on the prostate cancer antigen 3 assay. <i>European Urology</i> , <b>2013</b> , 63, 201-9	9.9	97
24	Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data. <i>European Urology</i> , <b>2013</b> , 64, 846-54	9.9	262
23	Long-term decrease in bladder cancer recurrence with hexaminolevulinate enabled fluorescence cystoscopy. <i>Journal of Urology</i> , <b>2012</b> , 188, 58-62	1.5	126
22	Radical prostatectomy is the most cost-effective primary treatment modality for men diagnosed with high-risk prostate cancer. <i>Canadian Urological Association Journal</i> , <b>2012</b> , 6, 396-8	1.2	2
21	Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA. <i>Science Translational Medicine</i> , <b>2011</b> , 3, 94ra72	16.9	282
20	Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with nonmuscle invasive bladder cancer. <i>Journal of Urology</i> , <b>2010</b> , 184, 1907-13	1.5	181

19	Reply to Juan Morote Letter to the Editor re: Felix K. Chun, Alexandre de la Taille, Hendrik van Poppel, et al. Prostate Cancer Gene 3 (PCA3): Development and Internal Validation of a Novel Biopsy Nomogram. <i>Eur Urol</i> 2009;56:659-67. <i>European Urology</i> , <b>2010</b> , 57, e2-e3	9.9	
18	Prostate cancer gene 3 (PCA3): development and internal validation of a novel biopsy nomogram. <i>European Urology</i> , <b>2009</b> , 56, 659-67	9.9	141
17	Biomarkers in prostate cancer diagnosis and prognosis: beyond prostate-specific antigen. <i>Current Opinion in Urology</i> , <b>2009</b> , 19, 243-6	2.7	37
16	The burden of prostate cancer in Canada. <i>Canadian Urological Association Journal</i> , <b>2009</b> , 3, S92-S100	1.2	26
15	PCA3: a molecular urine assay for predicting prostate biopsy outcome. <i>Journal of Urology</i> , <b>2008</b> , 179, 1587-92	1.5	345
14	PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy. <i>Urology</i> , <b>2007</b> , 69, 532-5	1.5	347
13	A phase III, multicenter comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of superficial papillary lesions in patients with bladder cancer. <i>Journal of Urology</i> , <b>2007</b> , 178, 62-7	1.5	212
12	A comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of carcinoma in situ in patients with bladder cancer: a phase III, multicenter study. <i>Journal of Urology</i> , <b>2007</b> , 178, 68-73; discussion 73	1.5	224
11	Identification of PCA3 (DD3) in prostatic carcinoma by in situ hybridization. <i>Modern Pathology</i> , <b>2007</b> , 20, 1121-7	9.4	53
10	Rebuttal: Should Canadians be offered systematic prostate cancer screening? YES. <i>Canadian Family Physician</i> , <b>2007</b> , 53, 1140-3	0.8	
9	Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers. <i>Urology</i> , <b>2005</b> , 66, 35-63	1.5	318
8	Prognostic markers for bladder cancer: International Consensus Panel on bladder tumor markers. <i>Urology</i> , <b>2005</b> , 66, 64-74	1.5	142
7	uPM3, a new molecular urine test for the detection of prostate cancer. <i>Urology</i> , <b>2004</b> , 64, 311-5; discussion 315-6	1.5	138
6	COMPARISON OF MOLECULAR AND CONVENTIONAL STRATEGIES FOR FOLLOWUP OF SUPERFICIAL BLADDER CANCER USING DECISION ANALYSIS. <i>Journal of Urology</i> , <b>2000</b> , 163, 752-757	1.5	31
5	Neoadjuvant hormonal therapy before radical prostatectomy and risk of prostate specific antigen failure. <i>Journal of Urology</i> , <b>1999</b> , 162, 2024-8	1.5	48
4	DOWNWARD TREND IN PROSTATE CANCER MORTALITY IN QUEBEC AND CANADA. <i>Journal of Urology</i> , <b>1999</b> , 161, 1189-1191	1.5	45
3	Diagnostic Accuracy of Urinary Cytology, and Deoxyribonucleic Acid Flow Cytometry and Cytology on Bladder Washings During Followup for Bladder Tumors. <i>Journal of Urology</i> , <b>1997</b> , 157, 1660-1664	1.5	63
2	Performance characteristics of a new monoclonal antibody test for bladder cancer: ImmunoCyt trade mark. <i>Canadian Journal of Urology</i> , <b>1997</b> , 4, 400-405	0.8	81

- 1 The treatment of prostate cancer: how is failure defined and how can it be minimized?. *Canadian Journal of Urology*, **1997**, 4, 39-43 0.8